Genomic tools for dissecting oncogenic transcriptional networks in human leukemia

Leukemia

Volumn 23, Issue 7, 2009, Pages 1236-1242

  Palomero, T ^a,b   Ferrando, A A ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; DNA BINDING PROTEIN; GAMMA SECRETASE INHIBITOR; GENOMIC DNA; GLUCOCORTICOID; HISTONE H3; INTERFERON REGULATORY FACTOR 4; MYC PROTEIN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 6; PROTEIN KINASE B; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR T BET; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANALYZER; B CELL LYMPHOMA; CHROMATIN IMMUNOPRECIPITATION; COMPUTER MODEL; DNA MICROARRAY; DNA MODIFICATION; DNA SEQUENCE; DRUG PROTEIN BINDING; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE REGULATORY NETWORK; GENE TARGETING; GENE TECHNOLOGY; GENETIC EPIGENESIS; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN DNA BINDING; REVIEW;

EID: 67651056489     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.394     Document Type: Review

References (82)

1. Teitell M, Pandolfi P. Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol 2008; 4.
2. Ferrando A, Look A. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol 2000; 37: 381-395.
3. Golub T, Slonim D, Tamayo P, Huard C, Gaasenbeek M, Mesirov J et al Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
4. Ferrando A, Neuberg D, Staunton J, Loh M, Huard C, Raimondi S et al Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
5. Yeoh E, Ross M, Shurtleff S, Williams W, Patel D, Mahfouz R et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-143.
6. Barski A, Cuddapah S, Cui K, Roh T, Schones D, Wang Z et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837.
7. Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol 2009; 41: 72-80.
8. Krivtsov A, Armstrong S. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007; 7: 823-833.
9. Griffiths E, Gore S. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008; 45: 23-30.
10. Atallah E, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol 2007; 5: 544-552.
11. Wang T, Tavera-Mendoza L, Laperriere D, Libby E, MacLeod N, Nagai Y et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005; 19: 2685-2695.
12. U M, Shen L, Oshida T, Miyauchi J, Yamada M, Miyashita T. Identification of novel direct transcriptional targets of glucocorticoid receptor. Leukemia 2004; 18: 1850-1856.
13. Park D, Vuong P, de Vos S, Douer D, Koeffler H. Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood 2003; 102: 3727-3736.
14. Wang D, Sevcikova S, Wen H, Roberts S, Lipsick J. v-Myb represses the transcription of Ets-2. Oncogene 2007; 26: 1238-1244.
15. Zeisig B, Milne T, García-Cuéllar M, Schreiner S, Martin M, Fuchs U et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004; 24: 617-628.
16. Grandori C, Gomez-Roman N, Felton-Edkins Z, Ngouenet C, Galloway D, Eisenman R et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 2005; 7: 311-318.
17. Tamura T, Thotakura P, Tanaka T, Ko M, Ozato K. Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages. Blood 2005; 106: 1938-1947.
18. Palomero T, Odom D, O'Neil J, Ferrando A, Margolin A, Neuberg D et al Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia. Blood 2006; 108: 986-992.
19. Smith R, Owen L, Trem D, Wong J, Whangbo J, Golub T et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006; 9: 405-416.
20. Hudson M, Snyder M. High-throughput methods of regulatory element discovery. Biotechniques 2006; 41: 673, 675, 677 passim.
21. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young R et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002; 16: 245-256.
22. Weinmann A, Yan P, Oberley M, Huang T, Farnham P. Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev 2002; 16: 235-244.
23. Weinmann A, Farnham P. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods 2002; 26: 37-47.
24. Martone R, Euskirchen G, Bertone P, Hartman S, Royce T, Luscombe N et al. Distribution of NF-kappaB-binding sites across human chromosome 22. Proc Natl Acad Sci USA 2003; 100: 12247-12252.
25. O'Neill LP, VerMilyea MD, Turner BM. Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations. Nat Genet 2006; 38: 835-841.
26. Kim TH, Barrera LO, Zheng M, Qu C, Singer MA, Richmond TA et al. A high-resolution map of active promoters in the human genome. Nature 2005; 436: 876-880.
27. Li W, Meyer CA, Liu XS. A hidden Markov model for analyzing ChIP-chip experiments on genome tiling arrays and its application to p53 binding sequences. Bioinformatics 2005; 21 (Suppl 1): I274-i282.
28. Gibbons FD, Proft M, Struhl K, Roth FP. Chipper: Discovering transcription-factor targets from chromatin immunoprecipitation microarrays using variance stabilization. Genome Biol 2005; 6 R96.
29. Qi Y, Rolfe A, MacIsaac KD, Gerber GK, Pokholok D, Zeitlinger J et al High-resolution computational models of genome binding events. Nat Biotechnol 2006; 24: 963-970.
30. Zheng M, Barrera L, Ren B, Wu Y. ChIP-chip: Data, model, and analysis. Biometrics 2007; 63: 787-796.
31. Yochum G, Cleland R, Goodman R. A genome-wide screen for {beta}-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol Cell Biol 2008; 28: 7368-7379.
32. Zeller K, Zhao X, Lee C, Chiu K, Yao F, Yustein J et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 2006; 103: 17834-17839.
33. Liu Y, Li F, Handler J, Huang C, Xiang Y, Neretti N et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS ONE 2008; 3: E2722.
34. Chi KR. The year of sequencing. Nat Methods 2008; 5: 11-14.
35. Mardis E. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008; 9: 387-402.
36. Boyle A, Davis S, Shulha H, Meltzer P, Margulies E, Weng Z et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 2008; 132: 311-322.
37. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T et al Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods 2007; 4: 651-657.
38. Johnson D, Mortazavi A, Myers R, Wold B. Genome-wide mapping of in vivo protein-DNA interactions. Science 2007; 316: 1497-1502.
39. Jothi R, Cuddapah S, Barski A, Cui K, Zhao K. Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data. Nucleic Acids Res 2008; 36: 5221-5231.
40. Valouev A, Johnson D, Sundquist A, Medina C, Anton E, Batzoglou S et al. Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat Methods 2008; 5: 829-834.
41. Schmidt D, Stark R, Wilson MD, Brown GD, Odom DT. Genomescale validation of deep-sequencing libraries. PLoS ONE 2008; 3: E3713.
42. Gangwal K, Sankar S, Hollenhorst P, Kinsey M, Haroldsen S, Shah A et al. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci USA 2008; 105: 10149-10154.
43. Truscott M, Harada R, Vadnais C, Robert F, Nepveu A. p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes. Mol Cell Biol 2008; 28: 3127-3138.
44. Leung J, Ehmann G, Giangrande P, Nevins J. A role for Myc in facilitating transcription activation by E2F1. Oncogene 2008; 27: 4172-4179.
45. Rabinovich A, Jin V, Rabinovich R, Xu X, Farnham P. E2F in vivo binding specificity: Comparison of consensus versus nonconsensus binding sites. Genome Res 2008; 18: 1763-1777.
46. Elnitski L, Jin V, Farnham P, Jones S. Locating mammalian transcription factor binding sites: A survey of computational and experimental techniques. Genome Res 2006; 16: 1455-1464.
47. Hayakawa J, Mittal S, Wang Y, Korkmaz KS, Adamson E, English C et al Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 2004; 16: 521-535.
48. Impey S, McCorkle S, Cha-Molstad H, Dwyer J, Yochum G, Boss J et al Defining the CREB regulon: A genome-wide analysis of transcription factor regulatory regions. Cell 2004; 119: 1041-1054.
49. Zhang X, Odom D, Koo S, Conkright M, Canettieri G, Best J et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci USA 2005; 102: 4459-4464.
50. Phuc Le P, Friedman JR, Schug J, Brestelli JE, Parker JB, Bochkis IM et al. Glucocorticoid receptor-dependent gene regulatory networks. PLoS Genet 2005; 1: E16.
51. Townsend M, Weinmann A, Matsuda J, Salomon R, Farnham P, Biron C et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004; 20: 477-494.
52. Beima K, Miazgowicz M, Lewis M, Yan P, Huang T, Weinmann A. T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects. J Biol Chem 2006; 281: 11992-12000.
53. Marson A, Kretschmer K, Frampton G, Jacobsen E, Polansky J, MacIsaac K et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445: 931-935.
54. Hug B, Ahmed N, Robbins J, Lazar M. A chromatin immunoprecipitation screen reveals protein kinase Cbeta as a direct RUNX1 target gene. J Biol Chem 2004; 279: 825-830.
55. Kim J, Chu J, Shen X, Wang J, Orkin S. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008; 132: 1049-1061.
56. O'Neil J, Look A. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene 2007; 26: 6838-6849.
57. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8: 380-390.
58. Elefanty A, Begley C, Hartley L, Papaevangeliou B, Robb L. SCL expression in the mouse embryo detected with a targeted lacZ reporter gene demonstrates its localization to hematopoietic, vascular, and neural tissues. Blood 1999; 94: 3754-3763.
59. Bash R, Hall S, Timmons C, Crist W, Amylon M, Smith R et al. Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A pediatric oncology group study. Blood 1995; 86: 666-676.
60. Kelliher M, Seldin D, Leder P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. EMBO J 1996; 15 5160-5166.
61. Condorelli G, Facchiano F, Valtieri M, Proietti E, Vitelli L, Lulli V et al. T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res 1996; 56: 5113-5119.
62. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 2004; 5: 587-596.
63. Palomero T, Lim W, Odom D, Sulis M, Real P, Margolin A et al. NOTCH1 directly regulates c-MYC and activates a feed-forwardloop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006; 103: 18261-18266.
64. Palomero T, Sulis M, Cortina M, Real P, Barnes K, Ciofani M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203-1210.
65. Ciofani M, Zúñiga-Pflücker J. Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat Immunol 2005; 6: 881-888.
66. Jarriault S, Brou C, Logeat F, Schroeter E, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature 1995; 377: 355-358.
67. Palomero T, Dominguez M, Ferrando A. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle 2008; 7: 965-970.
68. Palomero T, Ferrando A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res 2008; 14 5314-5317.
69. Li Z, Van Calcar S, Qu C, Cavenee W, Zhang M, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003; 100: 8164-8169.
70. Parekh S, Prive G, Melnick A. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leuk Lymphoma 2008; 49: 874-882.
71. Polo J, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally J et al Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2007; 104: 3207-3212.
72. Ranuncolo S, Polo J, Dierov J, Singer M, Kuo T, Greally J et al. Bcl6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007; 8: 705-714.
73. Phan R, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432: 635-639.
74. Phan R, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclindependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 2005; 6: 1054-1060.
75. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231.
76. Figueroa M, Reimers M, Thompson R, Ye K, Li Y, Selzer R et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS ONE 2008; 3: E1882.
77. Kuang S, Tong W, Yang H, Lin W, Lee M, Fang Z et al. Genomewide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 2008; 22: 1529-1538.
78. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G et al. Promoter hypermethylation of cancerrelated genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004; 104: 2492-2498.
79. Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San JoseEneriz E, Garate L et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 2007; 109: 3462-3469.
80. Guenther M, Jenner R, Chevalier B, Nakamura T, Croce C, Canaani E et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci USA 2005; 102: 8603-8608.
81. Acevedo L, Iniguez A, Holster H, Zhang X, Green R, Farnham P. Genome-scale ChIP-chip analysis using 10 000 human cells. Biotechniques 2007; 43: 791-797.
82. Pop M, Salzberg S. Bioinformatics challenges of new sequencing technology. Trends Genet 2008; 24: 142-149.